Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome.
Steffie M B PetersBastiaan M PrivéMaarten de BakkerFrank de LangeWalter JentzenAnnemarie EekConstantijn H J MuselaersNiven MehraJ Alfred WitjesMartin GotthardtJames NagarajahMark W KonijnenbergPublished in: European journal of nuclear medicine and molecular imaging (2021)
We successfully performed small lesion dosimetry and showed that the tumor sink effect in mHSPC patients is of less concern than was expected. Tumor-to-organ ratio of absorbed dose was high and tumor uptake correlates with PSA response. Additional treatment cycles are legitimate in terms of organ toxicity and could lead to better tumor response.